title: Vemurafenib as first line therapy in BRAF-mutated Langerhans cell histiocytosis.
authors.affiliation: Department of Internal Medicine and French Reference Center for Rare Auto-immune and Systemic Diseases, Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière Hospital, Paris, France; Université Pierre et Marie Curie, UPMC University Paris 6, Paris, France. Electronic address: julien.haroche@psl.aphp.fr.
authors.forename: Julien
authors.initials: J
authors.lastname: Haroche
authors.affiliation: Department of Internal Medicine and French Reference Center for Rare Auto-immune and Systemic Diseases, Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière Hospital, Paris, France; Université Pierre et Marie Curie, UPMC University Paris 6, Paris, France.
authors.forename: Fleur
authors.initials: F
authors.lastname: Cohen-Aubart
authors.affiliation: Research Unit (EA) EA4340 and Pathology Laboratory, Versailles University and AP-HP, Boulogne, France.
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Emile
authors.affiliation: Department of Pediatrics, AP-HP, Centre de Référence des Histiocytoses, Hôpital Trousseau, Paris, France.
authors.forename: Jean
authors.initials: J
authors.lastname: Donadieu
authors.affiliation: Department of Internal Medicine and French Reference Center for Rare Auto-immune and Systemic Diseases, Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière Hospital, Paris, France; Université Pierre et Marie Curie, UPMC University Paris 6, Paris, France.
authors.forename: Zahir
authors.initials: Z
authors.lastname: Amoura
mesh_terms: D005260:Female; D006646:Histiocytosis, Langerhans-Cell / Q000188:drug therapy* / Q000235:genetics*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*; D013449:Sulfonamides / Q000627:therapeutic use*
chemical_list: D007211:Indoles; D013449:Sulfonamides; D048493:Proto-Oncogene Proteins B-raf